News > Zydus Lifesciences gets USFDA nod to sell arterial hypertension drug Selexipag

Zydus Lifesciences gets USFDA nod to sell arterial hypertension drug Selexipag

Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension (PAH, high blood pressure in the vessels that carry blood to the lungs) to delay disease progression and reduce the risk of hospitalization for PAH. Selexipag tablet had annual sales of $577m in the US according to IQVIA data. The group now has 338 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04.